Clinicomycological study and efficacy of antifungal treatment in dernatophytosis.

Not yet recruiting

• Conditions: Local infection of the skin and subcutaneous tissue, unspecified,

• Registration Number: CTRI/2020/03/023959
• Lead Sponsor: GMERS Medical College And Hospital Gotri

Brief Summary

Superficialfungal infection due to dermatophytosis is one of the most common skininfections in the India.It is contagious. The dermatophytes are a group offungi that invade the superficial layer of epidermis and degrade thekeratinized tissues of skin, hair and nails in living animals including man,causing ring worm. (1)(2) But in rare cases they invade the deeper layer of thedermis and other organs. A dermatophyte infection results in increased skinproliferation, scaling, and epidermal thickening.

Dermatophytosisis the fungal infection of keratinized tissue. It is caused by three asexualgenera- Trichophyton, Epidermophyton, and Microsporum. Dermatophytes arefilamentous, keratinophilic, pathogenic fungi which are readily identified bymicroscopic examination of clinical specimen and can be cultured easily inlaboratory. Depending on their habitat, they can be categorized as geophilic,zoophilic and anthropophilic.Based upon the affected site, thesehave been classified clinically into tinea capitis (head), tinea facei (face),tinea barbae (beard), tinea corporis (body), tinea mannum (hand), tinea cruris(groin), tinea pedis (foot), and tinea unguium (nail).

Fluconazole,terbinafine, itraconazole are commonly used antifungal agent indermatophytosis. Resistance to these drugs is being seen increasingly when usedin conventional doses and duration.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-14
• Last Update Posted: 2020-12-03

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

Patients of either sex Patients 18 years or above Patient is suffering from dermatophyte infection diagnosed clinically Patient is suffering from dermatophyte infection in body and genitals Patients with scaling present on lesion Ability to give oral informed consent.

Exclusion Criteria

Patient has been treated with oral or topical antifungal agents in last 3 months Patient on steroid therapy Patient having H/o hypersensitivity to above mentioned drugs Pregnancy or lactating mother Patient having any abnormal CVS, Renal , Hepatic functions or uncontrolled Diabetes Mellitus or HIV Patient who can’t come for regular follow up.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ClinicalAnd Statistical Cure in pruritus, erythema and scaling score	ClinicalAnd Statistical Cure in pruritus, erythema and scaling score | Improvement in Global Assessment scale | Mycological cure by studying KOH | Outcome will be assessed after 1 year at the end of study | Patient will be follwed up after 15 days
Improvement in Global Assessment scaleMycological cure by studying KOH	ClinicalAnd Statistical Cure in pruritus, erythema and scaling score | Improvement in Global Assessment scale | Mycological cure by studying KOH | Outcome will be assessed after 1 year at the end of study | Patient will be follwed up after 15 days

Secondary Outcome Measures

Name	Time	Method
Improvement in global assessment score and mycological cure in koh	improvement in global assessment score and mycological cure in koh

Trial Locations

Locations (1)

Gmers medical college and hospital; 🇮🇳 Vadodara, GUJARAT, India

Gmers medical college and hospital

🇮🇳Vadodara, GUJARAT, India

Grishma fumtiwala

Principal investigator

8128281353

grishmafumtiwala13@gmail.com